Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
180.39
-5.77 (-3.10%)
At close: Jul 20, 2026, 4:00 PM EDT
180.00
-0.39 (-0.22%)
After-hours: Jul 20, 2026, 7:39 PM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
38.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.92B |
| BeOne Medicines AG | 5.74B |
| Incyte | 5.36B |
| argenx SE | 4.74B |
| Alnylam Pharmaceuticals | 4.29B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
RVMD News
- 3 days ago - Tango Therapeutics price target raised to $40 from $36 at Mizuho - TheFly
- 11 days ago - Revolution Medicines price target raised to $235 from $205 at Guggenheim - TheFly
- 13 days ago - EMA accelerates assessment of Revolution Medicines daraxonrasib - TheFly
- 13 days ago - European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process - GlobeNewsWire
- 13 days ago - EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill - Reuters
- 14 days ago - Revolution Medicines price target raised to $215 from $185 at Mizuho - TheFly
- 18 days ago - Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 - GlobeNewsWire
- 20 days ago - Revolution Medicines price target raised to $210 from $179 at Truist - TheFly